|
|
Profile
|
Delegates :
Takuya Yokokawa |
|
Incorporated :
February 1 , 2001 |
Paid in Capital :
1971 Million yen |
Employees :
25 人 |
Address :
A.i.Nihombashi EAST 3F, Nihonbashi hakozakichou 30-1, Chuou-ku TOKYO
〒103-0015
|
TEL/FAX :
+81-3-6264-8268 / +81-3-3668-7776 |
URL：
https://www.ppmx.com/en/ |
Attachment :
|
Mission/Background :
Perseus Proteomics Inc. was established in 2001 with a foundation built upon cutting-edge technology of The Research Center for Advanced Science and Technology of the University of Tokyo, and a diverse research network. Our business domains are 1) antibody drug discovery, 2)antibody research support, 3) antibody/reagent sales. In the development of mainstream antibody pharmaceuticals, we utilize the hybridoma technique, employing animal immunization to obtain superior antibodies, as well as the phage display method capable of producing fully human antibodies. We integrate our proprietary phage antibody library with our patented ICOS screening method to advance the development of pipeline projects with highly anticipated efficacy. |
|
Technology & Business
|
[Drug Discovery - Key Technologies]
In the development of antibody pharmaceuticals, a crucial element is the acquisition of antibodies that bind to antigens marking diseases such as cancer and immune disorders. Our company has constructed an extremely diverse antibody library and, by combining it with our unique antibody screening method, we are able to obtain highly functional antibodies. Additionally, we utilize the single B cell screening method for efficient antibody acquisition. By March 2025, the completion of a new antibody library will enable the decoding of full-length sequences via NGS. This advancement will facilitate the procurement of more complex antibodies and propel our company into future AI-driven drug discovery and new business ventures.
[Antibody/Reagents Sales]
We offer a complete range of 48 types of nuclear receptor antibodies, along with regularly launching new products. Please consider our company for high-quality monoclonal antibody production.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PPMX-T003
|
Phase1/2
|
Human antibody to Transferrin receptor 1 (TfR1). Target for polycythemia vera (PV) and aggressive NK-cell leukemia (ANKL)
|
Out-licensing activities ongoing for PV. Phase 1/2 for ANKL to complete in FY2026/3.
|
PPMX-T002
|
Preclinical
|
Radioisotope (RI) labelled antibody to CDH3. Target for solid tumor including ovarian cancer and biliary tract cancer.
|
Out-licensing activities ongoing.
|
PPMX-T004
|
Preclinical
|
Antibody drug conjugate (ADC) to CDH3. Target for solid tumor including ovarian cancer and biliary tract cancer.
|
Preliminary toxicity tests ongoing for deciding the optimized efficacy and toxicity.
|
Antibody research service and contract service
|
Service/Marketing
|
Antibody sequencing, antibody production service, and other services.
|
VHH recombinant antibody generation service to be provided in FY2025/3.
|
Antibody for research
|
Service/Marketing
|
48 types of nuclear receptor antibodies. Antibodies for ADC, transcription factors, and inflammation markers.
|
Anti-MMAE antibody launched. Another new product is coming soon.
|
|
Highlights
|
・We completed Phase 1 of PPMX-T003 for polycythemia vera in 2024 and are currently conducting out-licensing activities.
・The investigator-led Phase 1/2 for ANKL using PPMX-T003 is ongoing (the duration has been extended by one year until the end of March 2026). It was selected for an orphan drug discovery support program by AMED in February 2025 for continuation.
|
|
Alliance strategy
|
Our company is engaged in developing antibody drug discovery pipeline primarily focused on anticancer agents. If you are interested in licensing any of our pipeline projects, please feel free to contact us. Additionally, our company is contracted to produce pharmaceutical candidate antibodies, research antibodies, and perform various other antibody research services for both corporations and academic professionals.
Contact： https://www.ppmx.com/en/contact/
|
|
|